SLC6A3 and Parkinson disease: Dopamine transporter imaging (DaT) has been used in clinical practice to detect dopaminergic deficits in neuro-degenerative (ND) Parkinsonian syndromes (PS) including Parkinson disease (PD) and support the differential diagnosis of non-dopamine deficiency aetiologies (non-DDA) of Parkinsonism in cases of clinical uncertainty1,2.